GeNeuro (FRA:GEM) Other Stockholders Equity: €42.85 Mil (As of Dec. 2023)


FRA:GEM GeNeuro SA FRA:GEM
8 GF Score
Price €0.03
View Full Analysis

What is GeNeuro Other Stockholders Equity?

GeNeuro FRA:GEM 8 Other Stockholders Equity is €42.85 Mil as of Dec. 2023. GuruFocus rates FRA:GEM with a GF Score™ of 8/100.

GeNeuro's Other Stockholders Equity for the quarter that ended in Dec. 2023 was €42.85 Mil.

GeNeuro's quarterly Other Stockholders Equity declined from Dec. 2022 (€43.58 Mil) to Jun. 2023 (€43.30 Mil) and declined from Jun. 2023 (€43.30 Mil) to Dec. 2023 (€42.85 Mil).

GeNeuro's annual Other Stockholders Equity increased from Dec. 2021 (€42.56 Mil) to Dec. 2022 (€43.58 Mil) but then declined from Dec. 2022 (€43.58 Mil) to Dec. 2023 (€42.85 Mil).

GeNeuro Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for GeNeuro's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeNeuro Other Stockholders Equity Chart

GeNeuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.05 42.69 42.56 43.58 42.85

GeNeuro Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.56 43.37 43.58 43.30 42.85
FRA:GEM
8GF Score
GeNeuro SA FRA:GEM
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeNeuro Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €42.85 Mil mean?
GeNeuro (FRA:GEM) has a Other Stockholders Equity of €42.85 Mil as of Dec. 2023. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on GeNeuro and its competitors.
Is GeNeuro's Other Stockholders Equity too high?
GeNeuro's current Other Stockholders Equity is €42.85 Mil. Overall, GeNeuro has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does GeNeuro's Other Stockholders Equity compare to VRTX and REGN?
GeNeuro's Other Stockholders Equity of €42.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on GeNeuro and its competitors. GeNeuro's current Other Stockholders Equity is €42.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeNeuro stock overvalued right now?
GeNeuro (FRA:GEM) has a current Other Stockholders Equity of €42.85 Mil. The current Other Stockholders Equity is €42.85 Mil. GeNeuro's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For GeNeuro (FRA:GEM), the current Other Stockholders Equity is €42.85 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GeNeuro Business Description

Address 3 chemin du Pre-Fleur, Plan-les-Ouates, Geneva, CHE, 1228
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
8GF Score

Get the complete analysis for FRA:GEM

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price